Article
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
Respiratory medicine - 1 Jan 2000
Carnovale Vincenzo, Iacotucci Paola, Terlizzi Vito, Colangelo Carmela, Medio Pietro, Ferrillo Lorenza, De Gregorio Fabiola, Francalanci Michela, Taccetti Giovanni, Buonaurio Serena, d'Ippolito Marcella, Marsicovetere Giovanni, D'Andria Michele, Ferrara Nicola, Salvatore Donatello
Abstract excerpt
BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (E/T/I) is a cystic fibrosis transmembrane conductance regulator (CFTR) triple combination therapy used for the treatment of cystic fibrosis (CF) in patients aged ≥12 years who have at least one copy of the Phe508del mutation (F) in the CFTR gene or another mutation that is responsive to treatment with E/T/I. This study determined the effectiveness and safety of E/T/I...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.